- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | REGENTIS BIOMATERIALS LTD. - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| REGENTIS BIOMATERIALS Aktie jetzt für 0€ handeln | |||||
| 16.04. | Regentis Biomaterials Ltd: Regentis Implements Strategy for Commercial Deployment of GelrinC in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon | 934 | ACCESS Newswire | Collaboration with leading European orthopedic center in Italy supports GelrinC clinical adoptionRenowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellence... ► Artikel lesen | |
| 17.03. | Regentis Biomaterials Ltd: Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400% | 373 | ACCESS Newswire | Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this yearProprietary process is already patented in several countries and is pending... ► Artikel lesen | |
| 24.02. | REGENTIS BIOMATERIALS LTD. - 20-F, Annual and transition report of foreign private issuers | 3 | SEC Filings | ||
| 24.02. | Regentis Biomaterials Ltd: Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update | 708 | ACCESS Newswire | $7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinCAlready approved in Europe, GelrinC is expected... ► Artikel lesen | |
| 24.02. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 24.02. | Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch | 4 | Insider Monkey | ||
| 19.02. | Regentis Biomaterials Ltd: Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair | 358 | ACCESS Newswire | Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition... ► Artikel lesen | |
| 17.02. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 17.02. | Regentis Biomaterials Ltd: Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs | 622 | ACCESS Newswire | With CE Mark approval, GelrinC is slated for commercial launch in Europe in 2026New clinical sites to support engagement with leading orthopedic surgeons and centers of excellence in key European markets... ► Artikel lesen | |
| 04.02. | Regentis Biomaterials appoints new CFO | 1 | Seeking Alpha | ||
| 04.02. | Regentis Biomaterials Ltd: Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial | 421 | ACCESS Newswire | GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S.Ori Gon brings substantial... ► Artikel lesen | |
| 29.01. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.01. | Regentis Biomaterials Ltd: Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S. | 605 | ACCESS Newswire | New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programsGelrinC is set to transform cartilage repair market with... ► Artikel lesen | |
| 20.01. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 20.01. | Regentis Biomaterials Ltd: Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method | 771 | ACCESS Newswire | 2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage - widely regarded as the gold standard for durable joint functionThis... ► Artikel lesen | |
| 06.01. | Regentis Biomaterials Ltd: Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation | 442 | ACCESS Newswire | Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical trial, as a predefined endpointNew peer-reviewed data published in the scientific... ► Artikel lesen | |
| 06.01. | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 18.12.25 | Regentis Biomaterials Ltd: Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC | 455 | ACCESS Newswire | Patent protects ready to use liquid formulation of GerlinC which improves efficiency and focus for surgeons, resulting in a 10-minute procedureRobust IP portfolio includes 35 issued patents to date... ► Artikel lesen | |
| 18.12.25 | REGENTIS BIOMATERIALS LTD. - 6-K, Report of foreign issuer | 3 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ETON PHARMACEUTICALS | 28,910 | +19,86 % | Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 86,91 | -1,18 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| LB PHARMACEUTICALS | 31,355 | -1,12 % | This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| BIOHAVEN | 9,630 | +0,57 % | Biohaven Ltd.: Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM)... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,390 | -1,83 % | KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| AQUESTIVE THERAPEUTICS | 4,190 | +2,07 % | Vergessene Biotech-Chance: Kann Aquestive Therapeutics vor dem Durchbruch stehen? | Aquestive Therapeutics steht trotz operativer Fortschritte und potenziell wertvoller Pipeline unter massivem Bewertungsdruck. Die Aktie notiert deutlich unter früheren Kursniveaus, während sich fundamentale... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,340 | +4,46 % | Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning... ► Artikel lesen | |
| SHUTTLE PHARMACEUTICALS | 0,708 | -31,93 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation | Gaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin... ► Artikel lesen | |
| OMNIAB | 1,400 | +0,72 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| MILESTONE PHARMACEUTICALS | 1,870 | +3,89 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen | |
| JOURNEY MEDICAL | 5,185 | +0,68 % | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| DARE BIOSCIENCE | 2,350 | +3,07 % | Daré Bioscience, Inc.: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update | Company Highlights Commercial Launch of DARE to PLAY Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,110 | +3,80 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,905 | +0,79 % | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,400 | +4,93 % | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics... ► Artikel lesen |
REGENTIS BIOMATERIALS LTD gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 2,910 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REGENTIS BIOMATERIALS LTD finden Sie auf Wallstreet Online.